<DOC>
	<DOCNO>NCT02660060</DOCNO>
	<brief_summary>The present study conduct find whether bioavailability 0.25 mg pramipexole tablet produce PT Dexa Medica PT Ferron Par Pharmaceuticals equivalent reference drug ( Sifrol® tablet 0.25 mg , Boehringer Ingelheim Pharma GmbH &amp; Co. KG , Germany Boehringer Ingelheim International GmbH , Germany ) .</brief_summary>
	<brief_title>Bioequivalence Study Two Formulations Pramipexole Tablets 0.25 mg</brief_title>
	<detailed_description>This randomize , open label , two-period , two-sequence , crossover study fast condition . The participate subject require overnight fast next morning give orally one tablet test drug ( Pramipexole 0.25 mg produce PT Dexa Medica PT Ferron Par Pharmaceuticals ) one tablet reference drug ( Sifrol® 0.25 mg , Boehringer Ingelheim Pharma GmbH &amp; Co. KG , Germany Boehringer Ingelheim International GmbH , Germany ) . Blood sample draw immediately take drug ( control ) , 20 , 40 minute , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 12 , 16 , 24 , 36 , 48 hour drug administration . Seven day first drug administration ( washout period ) , procedure repeat use alternate drug . The plasma concentration pramipexole determine validated ultra performance liquid chromatography mass spectrometry detector ( UPLC-MS/MS ) .</detailed_description>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Healthy male female subject Preferably nonsmoker smoke less 10 cigarette per day Body mass index within 18 25 kg/m2 Normal vital sign ( 10 minute rest ) : systolic blood pressure 100 120 mmHg , diastolic blood pressure 60 80 mmHg , pulse rate 60 90 bpm Personal / family history allergy hypersensitivity contraindication pramipexole ally drug Pregnant lactate woman Any major illness past 90 day clinically significant ongoing chronic medical illness Any clinically significant abnormal value liver function test ( ALT , alkaline phosphatase , total bilirubin &gt; = 1.5 upper limit normal ) , renal function test ( serum creatinine &gt; 1.4 mg/dL ) , etc Positive Hepatitis B surface antigen ( HbsAg ) , antiHCV , antiHIV Clinically significant hematology abnormality Clinically significant ECG abnormalities Any surgical medical condition ( present history ) might significantly alter pharmacokinetics study drug History anaphylaxis angioedema History drug alcohol abuse within 12 month prior screen Participation clinical trial within past 90 day History bleed coagulative disorder History difficulty donate blood difficulty accessibility vein leave right arm A donation loss 300 mL ( ) blood within 3 month study 's first dose day Intake prescription , nonprescription drug , food supplement herbal medicine within 14 day study 's first dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pramipexole</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>